Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H17NO7 |
Molecular Weight | 371.3408 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC1=C2OC(=CC(=O)C2=CC3=C1N(CC)C(=CC3=O)C(O)=O)C(O)=O
InChI
InChIKey=RQTOOFIXOKYGAN-UHFFFAOYSA-N
InChI=1S/C19H17NO7/c1-3-5-9-16-10(13(21)7-12(18(23)24)20(16)4-2)6-11-14(22)8-15(19(25)26)27-17(9)11/h6-8H,3-5H2,1-2H3,(H,23,24)(H,25,26)
Molecular Formula | C19H17NO7 |
Molecular Weight | 371.3408 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00716 | https://www.drugs.com/ppa/nedocromil-sodium.html | http://reference.medscape.com/drug/alocril-nedocromil-ophthalmic-999594
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00716 | https://www.drugs.com/ppa/nedocromil-sodium.html | http://reference.medscape.com/drug/alocril-nedocromil-ophthalmic-999594
Nedocromil is a medication considered as mast cell stabilizer used to treat itching associated with allergic conjunctivitis. Nedocromil has been shown to inhibit the in vitro activation of, and mediator release from, a variety of inflammatory cell types associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets. Nedocromil inhibits activation and release of inflammatory mediators such as histamine, prostaglandin D2 and leukotrienes c4 from different types of cells in the lumen and mucosa of the bronchial tree. These mediators are derived from arachidonic acid metabolism through the lipoxygenase and cyclo-oxygenase pathways. The mechanism of action of nedocromil may be due partly to inhibition of axon reflexes and release of sensory neuropeptides, such as substance P, neurokinin A, and calcitonin-geneñrelated peptides. The result is inhibition of bradykinin-induced bronchoconstriction. Nedocromil does not possess any bronchodilator, antihistamine, or corticosteroid activity. Nedocromil is indicated for the treatment of itching associated with allergic conjunctivitis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0048245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9150324 |
|||
Target ID: GO:0043303 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26803520 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TILADE Approved UseALOCRIL ® ophthalmic solution is indicated for the treatment of itching associated with allergic conjunctivitis. Launch Date7.2567357E11 |
|||
Primary | TILADE Approved UseALOCRIL ® ophthalmic solution is indicated for the treatment of itching associated with allergic conjunctivitis. Launch Date7.2567357E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/ |
6 μg/kg bw single, intravenous dose: 6 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.1 ng/mL |
4 mg single, respiratory dose: 4 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
5.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/ |
70.5 mg single, oral dose: 70.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/ |
4 mg single, respiratory dose: 4 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.6 ng/mL |
20 mg single, respiratory dose: 20 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
3.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/ |
4 mg single, respiratory dose: 4 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
13.4 ng/mL |
0.42 mg single, intravenous dose: 0.42 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/ |
6 μg/kg bw single, intravenous dose: 6 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.6 ng × h/mL |
4 mg single, respiratory dose: 4 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
49.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/ |
70.5 mg single, oral dose: 70.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/ |
4 mg single, respiratory dose: 4 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6.2 ng × h/mL |
20 mg single, respiratory dose: 20 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
9.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/ |
4 mg single, respiratory dose: 4 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8.9 ng × h/mL |
0.42 mg single, intravenous dose: 0.42 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
21.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/ |
70.5 mg single, oral dose: 70.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/ |
4 mg single, respiratory dose: 4 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/ |
4 mg single, respiratory dose: 4 mg route of administration: Respiratory experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
31.6 h |
0.42 mg single, intravenous dose: 0.42 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEDOCROMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
2 % 2 times / day multiple, ophthalmic Highest studied dose Dose: 2 %, 2 times / day Route: ophthalmic Route: multiple Dose: 2 %, 2 times / day Sources: Page: CR 1957 |
unhealthy, 12-61 n = 289 Health Status: unhealthy Condition: allergic conjunctivitis Age Group: 12-61 Sex: M+F Population Size: 289 Sources: Page: CR 1957 |
Disc. AE: Eyeball itching, Swelling... AEs leading to discontinuation/dose reduction: Eyeball itching Sources: Page: CR 1957Swelling |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Eyeball itching | Disc. AE | 2 % 2 times / day multiple, ophthalmic Highest studied dose Dose: 2 %, 2 times / day Route: ophthalmic Route: multiple Dose: 2 %, 2 times / day Sources: Page: CR 1957 |
unhealthy, 12-61 n = 289 Health Status: unhealthy Condition: allergic conjunctivitis Age Group: 12-61 Sex: M+F Population Size: 289 Sources: Page: CR 1957 |
Swelling | Disc. AE | 2 % 2 times / day multiple, ophthalmic Highest studied dose Dose: 2 %, 2 times / day Route: ophthalmic Route: multiple Dose: 2 %, 2 times / day Sources: Page: CR 1957 |
unhealthy, 12-61 n = 289 Health Status: unhealthy Condition: allergic conjunctivitis Age Group: 12-61 Sex: M+F Population Size: 289 Sources: Page: CR 1957 |
PubMed
Title | Date | PubMed |
---|---|---|
Inhaled hyperosmolar agents for bronchiectasis. | 2001 |
|
Bronchial, alveolar, and vascular-induced anaphylaxis and irritant-induced cardiovascular and pulmonary responses. | 2001 Aug |
|
Double-blind, randomized, placebo-controlled trial of effect of nedocromil sodium on clinical and inflammatory parameters of asthma in children allergic to dust mite. | 2001 Jun |
|
Exhaled nitric oxide in seasonal allergic rhinitis: influence of pollen season and therapy. | 2001 Mar |
|
Dehydration behavior of nedocromil magnesium pentahydrate. | 2001 Mar 14 |
|
Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms. | 2001 Sep |
|
Water aerosols and cough. | 2002 |
|
Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age. | 2002 |
|
Twice-daily and once-daily nedocromil sodium 2% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. | 2002 Jan-Feb |
|
Review: nedocromil sodium decreases airflow reduction and recovery time in exercise-induced bronchoconstriction. | 2002 Sep-Oct |
|
Antiasthmatic effects of nedocromil sodium. | 2003 |
|
Single-dose agents in the prevention of exercise-induced asthma: a descriptive review. | 2004 |
|
Long-term effect of budesonide on hypothalamic-pituitary-adrenal axis function in children with mild to moderate asthma. | 2004 Jun |
|
Investigation into the mechanisms by which nedocromil sodium, frusemide and bumetanide inhibit the histamine-induced itch and flare response in human skin in vivo. | 2004 Mar |
|
The management of asthma and rhinitis during pregnancy. | 2005 Apr |
|
Respiratory morbidity in office workers in a water-damaged building. | 2005 Apr |
|
Asthma controller therapy during pregnancy. | 2005 Feb |
Sample Use Guides
Instill 1-2 gtt in each eye twice daily throughout time of exposure (ie, until pollen season is over or offending allergen terminated)
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9150324
Eosinophil chemotaxis was studied using a modified Boyden chamber technique. Sets of six chambers each were set up to investigate different experimental conditions. Half a millilitre of either medium 199, conditioned medium, or conditioned medium containing 10^-7, 10^-6 or 10^-5 M nedocromil sodium, was placed in the lower compartment of each chamber, and incubated for 90 min at 37°C in the presence of 2510^3 eosinophils in the upper compartment, separated by an 8 m pore size microporous polycarbonate membrane. At the end of incubation, the membrane was removed, fixed in absolute alcohol for 5 min and then washed under running tap water for 1 min. The membrane was stained with Chromotrope R for 5 min. The stained membrane was dehydrated in absolute alcohol for 5 min, cleared in CNP 30 reagent (BDH LaboratorySupplies, Lutterworth, UK), and then mounted in Styrolite™ mounting medium. The membrane was immediately examined by light microscopy, and the number of eosinophils coming through to the other side of the membrane was counted in 10 random high power fields (HPF) at x40 magnification.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:46:24 UTC 2023
by
admin
on
Fri Dec 15 15:46:24 UTC 2023
|
Record UNII |
0B535E0BN0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
||
|
WHO-VATC |
QR01AC07
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
||
|
NDF-RT |
N0000175628
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
||
|
WHO-VATC |
QR03BC03
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
||
|
WHO-ATC |
R01AC07
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
||
|
WHO-ATC |
R03BC03
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
||
|
NDF-RT |
N0000175630
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
||
|
WHO-VATC |
QS01GX04
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
||
|
WHO-ATC |
S01GX04
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D017835
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
31563
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | RxNorm | ||
|
0B535E0BN0
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
5420
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
DB00716
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
1889
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
Nedocromil
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
7492
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
SUB09179MIG
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
W-99
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
m7791
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | Merck Index | ||
|
DTXSID7023356
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
7607
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
NEDOCROMIL
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
100000084146
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
C66225
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
50294
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
69049-73-6
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
0B535E0BN0
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY | |||
|
CHEMBL746
Created by
admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||